Oculis (NASDAQ:OCS) Sets New 52-Week Low – Should You Sell?

Oculis Holding AG (NASDAQ:OCS)’s share price hit a new 52-week low during trading on Friday . The stock traded as low as $11.29 and last traded at $11.3170, with a volume of 284111 shares. The stock had previously closed at $11.83.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on OCS. Robert W. Baird lowered their price objective on Oculis from $49.00 to $38.00 and set an “outperform” rating for the company in a research note on Monday, June 1st. JPMorgan Chase & Co. lowered their price objective on Oculis from $42.00 to $23.00 and set an “overweight” rating for the company in a research note on Wednesday. Needham & Company LLC lowered their price objective on Oculis from $46.00 to $38.00 and set a “buy” rating for the company in a research note on Monday, June 1st. HC Wainwright lowered their price objective on Oculis from $47.00 to $26.00 and set a “buy” rating for the company in a research note on Monday, June 1st. Finally, Stifel Nicolaus lowered their price objective on Oculis from $50.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, June 1st. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Oculis currently has an average rating of “Moderate Buy” and a consensus target price of $38.33.

Oculis Trading Down 5.2%

The company has a quick ratio of 5.18, a current ratio of 5.18 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $649.96 million, a PE ratio of -5.26 and a beta of 0.23. The firm has a 50 day moving average price of $26.45 and a 200 day moving average price of $24.94.

Oculis (NASDAQ:OCS) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). The business had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.25 million. Oculis had a negative return on equity of 56.78% and a negative net margin of 8,460.67%. Equities analysts expect that Oculis Holding AG will post -2.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. grew its stake in Oculis by 100.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock valued at $40,000 after purchasing an additional 1,000 shares during the period. Aventura Private Wealth LLC bought a new position in Oculis in the 4th quarter valued at $80,000. Koshinski Asset Management Inc. bought a new position in Oculis in the 1st quarter valued at $238,000. Millennium Management LLC bought a new position in Oculis in the 4th quarter valued at $312,000. Finally, Marshall Wace LLP bought a new position in Oculis in the 2nd quarter valued at $393,000. Institutional investors own 22.30% of the company’s stock.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.